Cholesterol Triggers Nuclear Co-Association of Androgen Receptor, p160 Steroid Coactivators, and p300/CBP-Associated Factor Leading to Androgenic Axis Transactivation in Castration-Resistant Prostate Cancer

Imagem de Miniatura
Arquivos
art_PIMENTA_Cholesterol_Triggers_Nuclear_CoAssociation_of_Androgen_Receptor_p160_2022.PDF (2.44 MB)
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
CELL PHYSIOL BIOCHEM PRESS GMBH CO KG
Autores
GONçALVES, G. L.
Citação
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, v.56, p.1-15, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background/Aims: Cholesterol modulates intratumoral androgenic signaling in prostate cancer; however, the molecular mechanisms underlying these changes in castration-resistant prostate cancer (CRPC) are not fully elucidated. Herein, we investigated the effect of cholesterol on androgen receptor (AR) coactivators expression and tumorigenesis in vitro and in vivo. Methods: Herein, we monitored the expression of AR coactivators (SRC-1, 2, 3 and PCAF) genes in PC-3 cells exposed to 2µg/mL of cholesterol for 8 hours by qPCR. We also performed cell migration at 0, 8, 24, 48 and 72h and flow cytometry assays (viability, apoptosis, and cell cycle) after a 24h exposure. Immunofluorescence assay was performed to evaluate the protein expression of the AR coactivators. Additionally, in vivo experiments were conducted using 22 male NOD/SCID mice. Mice were fed a standard (Control) or hypercholesterolemic (HCOL) diet for 21 days and then subcutaneously implanted with PC-3 cells. The tumor volume was calculated every two days, and after four weeks, the tumors were resected, weighed, and the serum lipid profile was measured. We also measured the intratumoral lipid profile and AR coactivators gene and protein expression by qPCR and Western Blot, respectively. Intratumor testosterone and dihydrotestosterone (DHT) concentrations were determined using ELISA. Results: Cholesterol up-regulated the gene expression of coactivators SRC-1, SRC-2, SRC-3 and PCAF, increasing AR expression in PC-3 cells. Next, cholesterol-supplemented PC-3 cells exhibited increased cell migration and altered cell cycle phases, leading to changes in proliferation and reduced apoptosis. We found that SRC-1, SRC-2, SRC-3 and PCAF proteins co-localized in the nucleus of cholesterol-supplemented cells and co-associate with AR. In the in vivo model, the hypercholesterolemic (HCOL) group displayed higher serum total and intratumoral cholesterol levels, increased testosterone and dihydrotestosterone concentrations, and up-regulated AR coactivator expression. The tumor volume of the HCOL group was significantly higher than the control group. Conclusion: Our findings revealed that increased nuclear translocation of the coactivators leads to up-regulated AR gene and protein expression, potentially influencing tumor progression. Studies targeting cholesterol-modulated changes in AR coactivator expression may provide insights into the molecular mechanisms associated with the CRPC phenotype. © 2022 Cell Physiol Biochem Press GmbH & Co KG. All rights reserved.
Palavras-chave
Hypercholesterolemic model, p160, Prostate cancer
URI
https://observatorio.fm.usp.br/handle/OPI/51838
Referências
  1. So, A, Gleave, M, Hurtado-Col, A, Nelson, C, Mechanisms of the development of androgen independence in prostate cancer (2005) World J Urol, 23, pp. 1-9
  2. Dillard, PR, Lin, MF, Khan, SA, Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol (2008) Mol Cell Endocrinol, 295, pp. 115-120
  3. Fedoruk, MN, Giménez-Bonafé, P, Guns, ES, Mayer, LD, Nelson, CC, P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells (2004) Prostate, 59, pp. 77-90
  4. Culig, Z, Androgen receptor cross-talk with cell signalling pathways (2004) Growth Factors, 22, pp. 179-184
  5. Chmelar, R, Buchanan, G, Need, EF, Tilley, W, Greenberg, NM, Androgen receptor coregulators and their involvement in the development and progression of prostate cancer (2007) Int J Cancer, 120, pp. 719-733
  6. Han, G, Buchanan, G, Ittmann, M, Harris, JM, Yu, X, Demayo, FJ, Tilley, W, Greenberg, NM, Mutation of the androgen receptor causes oncogenic transformation of the prostate (2005) Proc Natl Acad Sci U S A, 102, pp. 1151-1156
  7. Feldman, BJ, Feldman, D, The development of androgen-independent prostate cancer (2001) Nat Rev Cancer, 1, pp. 34-45
  8. McKenna, NJ, O’Malley, BW, Combinatorial control of gene expression by nuclear receptors and coregulators (2002) Cell, 108, pp. 465-474
  9. Linja, MJ, Porkka, KP, Kang, Z, Savinainen, KJ, Jänne, OA, Tammela, TL, Vessella, RL, Visakorpi, T, Expression of androgen receptor coregulators in prostate cancer (2004) Clin Cancer Res, 10, pp. 1032-1040
  10. Xu, J, Wu, RC, O’Malley, BW, Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family (2009) Nat Rev Cancer, 9, pp. 615-630
  11. McKenna, NJ, O’Malley, BW, Minireview: nuclear receptor coactivators-an update (2002) Endocrinology, 143, pp. 2461-2465
  12. Foley, C, Mitsiades, N, Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer (2016) Horm Cancer, 7, pp. 84-103
  13. Yan, J, Erdem, H, Li, R, Cai, Y, Ayala, G, Ittmann, M, Yu-Lee, LY, Tsai, MJ, Steroid receptor coactivator-3/ AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression (2008) Cancer Res, 68, pp. 5460-5468
  14. Dasgupta, S, Putluri, N, Long, W, Zhang, B, Wang, J, Kaushik, AK, Arnold, JM, O’Malley, BW, Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis (2015) J Clin Invest, 125, pp. 1174-1188
  15. Isharwal, S, Miller, MC, Marlow, C, Makarov, DV, Partin, AW, Veltri, RW, p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape (2008) Prostate, 68, pp. 1097-1104
  16. Comuzzi, B, Nemes, C, Schmidt, S, Jasarevic, Z, Lodde, M, Pycha, A, Bartsch, G, Hobisch, A, The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer (2004) J Pathol, 204, pp. 159-166
  17. Gregory, CW, He, B, Johnson, RT, Ford, OH, Mohler, JL, French, FS, Wilson, EM, A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy (2001) Cancer Res, 61, pp. 4315-4319
  18. Culig, Z, Steiner, H, Bartsch, G, Hobisch, A, Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours (2005) Endocr Relat Cancer, 12, pp. 229-244
  19. Debes, JD, Schmidt, LJ, Huang, H, Tindall, DJ, p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6 (2002) Cancer Res, 62, pp. 5632-5636
  20. Swinnen, JV, Heemers, H, Heyns, W, Verhoeven, G, Androgen regulation of lipogenesis (2002) Adv Exp Med Biol, 506, pp. 379-387
  21. Mah, CY, Nassar, ZD, Swinnen, JV, Butler, LM, Lipogenic effects of androgen signaling in normal and malignant prostate (2020) Asian J Urol, 7, pp. 258-270
  22. Moon, H, Ruelcke, JE, Choi, E, Sharpe, LJ, Nassar, ZD, Bielefeldt-Ohmann, H, Parat, MO, Hill, MM, Diet-induced hypercholesterolemia promotes androgen-independent prostate cancer metastasis via IQGAP1 and caveolin-1 (2015) Oncotarget, 6, pp. 7438-7453
  23. Rocha, GZ, Dias, MM, Ropelle, ER, Osório-Costa, F, Rossato, FA, Vercesi, AE, Saad, MJ, Carvalheira, JB, Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth (2011) Clin Cancer Res, 17, pp. 3993-4005
  24. Saylor, PJ, Smith, MR, Metabolic complications of androgen deprivation therapy for prostate cancer (2013) J Urol, 189, pp. S34-S42. , discussion S43-34
  25. Alfaqih, MA, Allott, EH, Hamilton, RJ, Freeman, MR, Freedland, SJ, The current evidence on statin use and prostate cancer prevention: are we there yet? (2017) Nat Rev Urol, 14, pp. 107-119
  26. Jamnagerwalla, J, Howard, LE, Allott, EH, Vidal, AC, Moreira, DM, Castro-Santamaria, R, Andriole, GL, Freedland, SJ, Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study (2018) Prostate Cancer Prostatic Dis, 21, pp. 252-259
  27. Awad, AB, Fink, CS, Williams, H, Kim, U, In vitro and in vivo (SCID mice) effects of phytosterols on the growth and dissemination of human prostate cancer PC-3 cells (2001) Eur J Cancer Prev, 10, pp. 507-513
  28. Armandari, I, Hamid, AR, Verhaegh, G, Schalken, J, Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy (2014) Prostate Int, 2, pp. 105-113
  29. Agoulnik, IU, Vaid, A, Bingman, WE, Erdeme, H, Frolov, A, Smith, CL, Ayala, G, Weigel, NL, Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression (2005) Cancer Res, 65, pp. 7959-7967
  30. Dasgupta, S, Lonard, DM, O’Malley, BW, Nuclear receptor coactivators: master regulators of human health and disease (2014) Annu Rev Med, 65, pp. 279-292
  31. Zhou, HJ, Yan, J, Luo, W, Ayala, G, Lin, SH, Erdem, H, Ittmann, M, Tsai, MJ, SRC-3 is required for prostate cancer cell proliferation and survival (2005) Cancer Res, 65, pp. 7976-7983
  32. Louet, JF, Coste, A, Amazit, L, Tannour-Louet, M, Wu, RC, Tsai, SY, Tsai, MJ, O’Malley, BW, Oncogenic steroid receptor coactivator-3 is a key regulator of the white adipogenic program (2006) Proc Natl Acad Sci U S A, 103, pp. 17868-17873
  33. Jin, L, Garcia, J, Chan, E, de la Cruz, C, Segal, E, Merchant, M, Kharbanda, S, Gascoigne, KE, Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer (2017) Cancer Res, 77, pp. 5564-5575
  34. Lavery, DN, Bevan, CL, Androgen receptor signalling in prostate cancer: the functional consequences of acetylation (2011) J Biomed Biotechnol, 2011, p. 862125
  35. Lee, SO, Chun, JY, Nadiminty, N, Lou, W, Feng, S, Gao, AC, Interleukin-4 activates androgen receptor through CBP/p30 (2009) Prostate, 69, pp. 126-132
  36. Gu, ML, Wang, YM, Zhou, XX, Yao, HP, Zheng, S, Xiang, Z, Ji, F, An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells (2016) Oncol Rep, 36, pp. 2763-2770
  37. Russell, DW, Wilson, JD, Steroid 5 alpha-reductase: two genes/two enzymes (1994) Annu Rev Biochem, 63, pp. 25-61
  38. Chang, KH, Li, R, Papari-Zareei, M, Watumull, L, Zhao, YD, Auchus, RJ, Sharifi, N, Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer (2011) Proc Natl Acad Sci U S A, 108, pp. 13728-13733
  39. Kaighn, ME, Narayan, KS, Ohnuki, Y, Lechner, JF, Jones, LW, Establishment and characterization of a human prostatic carcinoma cell line (PC-3) (1979) Invest Urol, 17, pp. 16-23
  40. Castagnetta, L, Carruba, G, Granata, OM, Lo Casto, M, Arcuri, F, Mesiti, M, Pavone-Macaluso, M, Prostate long-term epithelial cell lines. Biological and biochemical features (1990) Ann N Y Acad Sci, 595, pp. 149-164
  41. Pimenta, RC, Viana, NI, Amaral, GQ, Park, R, Morais, DR, Pontes, J, Guimaraes, VR, Reis, ST, MicroRNA-23b and microRNA-27b plus flutamide treatment enhances apoptosis rate and decreases CCNG1 expression in a castration-resistant prostate cancer cell line (2018) Tumour Biol, 40. , 1010428318803011
  42. Culig, Z, Klocker, H, Eberle, J, Kaspar, F, Hobisch, A, Cronauer, MV, Bartsch, G, DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction (1993) Prostate, 22, pp. 11-22
  43. Sica, G, Dell’Acqua, G, Iacopino, F, Fattorossi, A, Marchetti, P, van der Kwast, TH, Pavone-Macaluso, M, Androgen receptors and hormone sensitivity of a human prostatic cancer cell line (PC-3) are modulated by natural beta-interferon (1994) Urol Res, 22, pp. 33-38
  44. Alimirah, F, Chen, J, Basrawala, Z, Xin, H, Choubey, D, DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation (2006) FEBS Lett, 580, pp. 2294-2300
  45. Fiandalo, MV, Wilton, J, Mohler, JL, Roles for the backdoor pathway of androgen metabolism in prostate cancer response to castration and drug treatment (2014) Int J Biol Sci, 10, pp. 596-601

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/26
Artigos e Materiais de Revistas Científicas - LIM/55
Artigos e Materiais de Revistas Científicas - ODS/03